RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
October 20, 2016 02:30 ET | RadioMedix Inc.
Houston, TX, Oct. 20, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston,TX)  is excited to announce the completion of  the Phase I/II  clinical  trial of AminoMedix ™ proprietary formulation used...